Review Article
Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis
Table 2
Subgroup analyses stratified by TNFi types and assay methods for ADAb detection.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TNFi: tumor necrosis factor inhibitors; ADAL: adalimumab; INF: infliximab; ETN: etanercept; combine: INF/ETN/ADAL; OR: odds ratio; CI: confidence interval; R: randomized-effects model; F: fixed-effects model; —: no model was used; NA: not available; ELISA: enzyme-linked immunosorbent assay; RIA: radioimmunoassay; IMPACT: Immunological Multi-Parameter Chip Technology. |